full year 2022 financial results

Wednesday February 8

Conference call at 13.00 CET / 7AM EST

To participate, please use the following dial ins:

DK: +45 78768490

UK: +44 2037696819

US: +1 6467870157

PIN: 930586

Watch the webcast

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our Science

LATEST NEWS

07 February, 2023 Corporate Release
Lundbeck delivers record revenue of DKK 18.2 billion and grows 12% in 2022
07 February, 2023 Corporate Release
Lundbeck announces financial guidance for 2023 and mid-term financial targets that build on very strong 2022 performance
12 January, 2023 Corporate Release
Thomas Gibbs to join Lundbeck as Executive Vice President and Head of Lundbeck in the United States

See All News

Come join us in making a difference to patients worldwide.

Job Opportunities

Explore the latest financial developments at Lundbeck.

Investors

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease.

Patients

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

Mara Formentini on working at Lundbeck

Bringing Your Whole Self to Work and its Rewards

See All Stories

Lundbeck at a glance

100

countries where our products are sold

5,300

employees supporting our purpose

1915

year Lundbeck was founded

No Health Without Mental Health

We need every brain in the game

Out of the Silence: Speaking Up About Migraine